Division of Rhinology and Sinus Surgery, Oregon Sinus Center, Department of Otolaryngology-Head and Neck Surgery, Portland, OR 97239, USA.
Int Forum Allergy Rhinol. 2013 Jan;3(1):4-9. doi: 10.1002/alr.21065. Epub 2012 Jun 26.
This study evaluated 1-year outcomes in patients with chronic rhinosinusitis (CRS) who were considered surgical candidates by study criteria and elected either medical management or endoscopic sinus surgery (ESS). In addition, some patients initially enrolled in the medical treatment arm crossed over to the surgery arm during the study period and their respective outcomes are evaluated.
Adult subjects with CRS who failed initial medical therapy were prospectively enrolled into a nonrandomized, multi-institutional cohort. Subjects were included in 1 of 3 cohorts: medically managed, surgically managed, or crossover (from medical to surgical). The primary outcome measure was disease-specific quality-of-life (QOL). Bivariate and multivariate analyses compared QOL improvement between cohort groups.
Baseline comorbidity, QOL, and other disease severity measures were not different between the 3 cohorts. With 1-year follow up, surgical patients (n = 65) reported significantly more improvement than medically managed patients (n = 33; Rhinosinusitis Disability Index (RSDI), p = 0.039; Chronic Sinusitis Survey (CSS), p = 0.018). Seventeen subjects who had initially elected medical management crossed over to surgery during the follow-up period. QOL in the crossover cohort was initially stagnant or worsening followed by improvement after ESS (RSDI, p = 0.035; CSS, p = 0.070). At 1-year follow-up, higher frequency of improvement was found in the surgical cohort vs medical cohort for several outcomes (total CSS: 70.8% vs 45.5%; odds ratio [OR], 3.37; 95% confidence interval [CI], 1.27-8.90; p = 0.014).
With 1 year of follow-up, patients electing ESS experienced significantly higher levels of improvement in outcomes compared to patients managed by medication alone. In addition, a crossover cohort who initially elected medical management experienced improvement in several outcomes after crossing over to ESS.
本研究评估了符合研究标准并选择药物治疗或内镜鼻窦手术(ESS)的慢性鼻-鼻窦炎(CRS)患者的 1 年疗效。此外,一些最初入组药物治疗组的患者在研究期间交叉到手术组,评估其各自的疗效。
患有 CRS 的成年患者在初始药物治疗失败后,前瞻性地被纳入非随机、多机构队列研究。患者被纳入以下 3 个队列之一:药物治疗组、手术治疗组或交叉组(从药物治疗到手术治疗)。主要疗效指标是疾病特异性生活质量(QOL)。对队列组间 QOL 改善进行了双变量和多变量分析。
基线合并症、QOL 和其他疾病严重程度指标在 3 个队列间无差异。在 1 年随访时,手术组(n=65)患者报告的改善明显优于药物治疗组(n=33)患者(Rhinossinusitis Disability Index,RSDI,p=0.039;Chronic Sinusitis Survey,CSS,p=0.018)。在随访期间,17 名最初选择药物治疗的患者交叉到手术组。交叉组的 QOL 最初停滞或恶化,随后 ESS 后改善(RSDI,p=0.035;CSS,p=0.070)。在 1 年随访时,与药物治疗组相比,手术组在几个结局方面的改善频率更高(总 CSS:70.8% vs 45.5%;优势比[OR],3.37;95%置信区间[CI],1.27-8.90;p=0.014)。
在 1 年随访时,选择 ESS 的患者与仅接受药物治疗的患者相比,其结局改善水平显著更高。此外,最初选择药物治疗的交叉组患者在交叉到 ESS 后,几个结局方面的改善。